Kei Kishimoto

Kei Kishimoto

Company: Selecta Bioscience

Job title: Chief Scientific Officer

Seminars:

PANEL Q&A: An Overview & Assessment of Current & Future Strategies to Circumvent or Lessen the Innate & Early Adaptive Immune Response to Gene Therapy 12:30 pm

Read more

day: Re-Dosing Discussion Day

Mitigation Of AAV Vector Immunogenicity With Tolerogenic Immtor Nanoparticles 11:30 am

ImmTOR nanoparticles encapsulating rapamycin induce antigen-specific immune tolerance Enhancement of liver-directed transgene expression observed at both initial and repeat doses of AAV vectors ImmTOR nanoparticles currently in Phase 3 trials with an immunogenic uricase enzyme therapy for the treatment of refractory goutRead more

day: Re-Dosing Discussion Day

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.